Oculogica is highlighted in the Community section under the headline The Future of Healthcare “Tracking a person’s eye movements to diagnose brain injuries” with Dr. Uzma Samadani of Oculogica. Read the entire article here:
Sofia Fund News & Blog
Sofia Fund Invests in Landit
Minneapolis, MN, February 28, 2019 — Sofia Fund, a leading angel investment group focused on high-growth, women-led companies, today announced its most recent investment in Landit, a technology platform that increases the success and engagement of women and diverse groups in the workplace.…
Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™
Pittsburgh, PA, February 21, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders, today announced the issuance by the European Patent Office of a composition of matter patent covering Elayta™, Cognition’s lead clinical stage compound in development for individuals with Alzheimer’s disease. …
Oculogica mentioned in February 19, 2019 issue of JAMA
Oculogica is the first highlight of the JAMA news section in this week’s issue: https://jamanetwork.com/journals/jama/fullarticle/2725217
Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement
Pittsburgh, PA, February 19, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1 trial of Elayta™ (CT1812) in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.…
Sofia Fund portfolio company Oculogica achieves FDA milestone
Oculogica receives FDA Marketing Authorization for EyeBOX®, the first non-invasive, baseline-free test for concussion. Oculogica is a pioneer in algorithm-based neurodiagnostics.
Blog Part III: The Right Investor Opens Their Wallet and Their Network
Third blog in a series by Joy Lindsay, Managing Partner, Sofia Fund. View Blog I here and Blog II here.
In my first two blogs of this three-part series, I covered two very important attributes that the right investor for your business should be able to offer – business acumen in running a company in your industry, and help in structuring and executing your financing strategy.…
Blog Part II: Start with the Right Investor to Have a Happy Ending
Second blog in a series by Joy Lindsay, Managing Partner, Sofia Fund. View Blog I here and Blog III here.
As a startup looking for capital, due diligence done by an entrepreneur is as important as due diligence done by the investor looking to invest in the business.…
CogRX receives $16.6M Grant for Phase II Study of Alzheimer’s Drug
Sofia Fund portfolio company CogRX has received a $16.6M Multi-Year Grant for Phase II studies of its Elayta™ drug for mild-to-moderate Alzheimer’s disease. Learn more at CogRX announces NIA grant…
Blog Part I- Show Me the Money… and More
First blog in a series by Joy Lindsay, Managing Partner, Sofia Fund. View Blog II here and Blog III here.
Follow the money, but find the fit. It’s advice I’ve been giving to entrepreneurs for more than 20 years.
The right investor can offer so much more to an entrepreneur and her business than simply cash.…